Form 4: KalVista Pharmaceuticals Director William Fairey Acquires 17,000 Stock Options
SEC Form 4 Filing
Director William Fairey acquired 17,000 stock options in KalVista Pharmaceuticals on April 18, 2024.
Summary
- On April 18, 2024, William Fairey, a director of KalVista Pharmaceuticals, acquired 17,000 stock options.
- The options have an exercise price of $11.50.
- The options vest monthly over a 36-month period, starting May 18, 2024, subject to continued service.
- The options expire on April 17, 2034.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, and does not inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 04/18/2024 | Date of transaction: William Fairey acquired 17,000 stock options. |
| 05/18/2024 | First vesting date: 1/36th of the options vest. |
| 04/17/2034 | Expiration date of the stock options. |
| 04/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.